登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由汕头大学医学院附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07339488,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.
入选标准第 4 条
ECOG performance status score of 0-1.
入选标准第 3 条
WBC≥3×10⁹/L
入选标准第 12 条
ALT and AST≤2.5×ULN
入选标准第 13 条
TBIL≤1.5×ULN
入选标准第 14 条
SCr≤1.5×ULN; or CrCl≥60 mL/min Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3/FT4 levels should also be considered; eligible if FT3/FT4 are normal) Echocardiography: LVEF≥50%
入选标准第 15 条
Active hepatitis B, hepatitis C, HIV, or syphilis.
排除标准第 8 条
Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.
入选标准第 16 条
Pregnant or lactating women.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07339488,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance. Age ≥18 years and ≤75 years; both sexes are eligible. ECOG performance status score of 0-1. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery. Thoracic esophageal cancer. Unresectable lesions, defined as: T4 stage; Borderline resectable T3 disease, in which imaging cannot exclude invasion of adjacent organs or structures, such as the trachea, bronchi, or aorta; T3 disease with supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy. Baseline laboratory requirements (within 7 days prior to enrollment): Hb≥90 g/L (no transfusion within 14 days) NEUT ≥1.5×10⁹/L PLT ≥100×10⁹/L WBC≥3×10⁹/L ALT and AST≤2.5×ULN TBIL≤1.5×ULN SCr≤1.5×ULN; or CrCl≥60 mL/min Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3/FT4 levels should also be considered; eligible if FT3/FT4 are normal) Echocardiography: LVEF≥50% Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study. No psychological, familial, social, or geographical factors that may impair protocol adherence. Other parameters meet general clinical trial enrollment criteria. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.排除标准:Exclusion Criteria:
Patients with distant metastases other than supraclavicular lymph node metastases. Presence or high risk of esophageal perforation. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment. Respiratory depression, airway obstruction, or tissue hypoxia. Severe cardiac disease (i.e., NYHA functional class II or higher). Markedly abnormal liver or kidney function (i.e., indicators >3 times the upper limit of normal). Active hepatitis B, hepatitis C, HIV, or syphilis. Active brain disease or central nervous system/meningeal metastases with significant symptoms, or impaired decision-making capacity. Hypersensitivity to drugs included in the trial. Drug and/or alcohol abuse. Pregnant or lactating women. Concurrent participation in another therapeutic clinical trial. Major surgical procedure within 30 days prior to enrollment. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.
引自 ClinicalTrials.gov, NCT07339488, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07339488,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。